Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Switzerland
/
Pharmaceuticals & Biotech
/
Siegfried Holding
SFZN
Siegfried Holding
Protectionism And Regulations Will Squeeze Margins But Spur Resilience
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 10 Analysts
Published
27 Jun 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CHF 94.50
7.4% undervalued
intrinsic discount
16 Aug
CHF 87.50
Loading
1Y
-12.4%
7D
0.8%
Author's Valuation
CHF 94.5
7.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CHF 94.5
7.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
2b
2014
2017
2020
2023
2025
2026
2028
Revenue CHF 1.5b
Earnings CHF 208.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
6.76%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.39%
Calculation
CHF 208.52m
Earnings '28
x
23.72x
PE Ratio '28
=
CHF 4.95b
Market Cap '28
CHF 4.95b
Market Cap '28
/
46.81m
No. shares '28
=
CHF 105.64
Share Price '28
CHF 105.64
Share Price '28
Discounted to 2025 @ 4.39% p.a.
=
CHF 92.86
Fair Value '25